Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

被引：0

作者：

Mian, Hira ^{[1
]}

LeBlanc, Richard ^{[2
]}

Louzada, Martha ^{[3
]}

Masih-Khan, Esther ^{[4
,5
]}

McCurdy, Arleigh ^{[6
]}

Venner, Christopher P. ^{[7
]}

Stakiw, Julie ^{[8
]}

Kardjadj, Moustafa ^{[4
]}

Jimenez-Zepeda, Victor H. ^{[9
]}

Sebag, Michael ^{[10
]}

White, Darrell ^{[11
]}

Aslam, Muhammad ^{[12
]}

Song, Kevin ^{[13
]}

Reiman, Anthony ^{[14
]}

Kotb, Rami ^{[15
]}

Gul, Engin ^{[4
]}

Reece, Donna ^{[4
,5
]}

机构：

[1] McMaster Univ, Hamilton, ON, Canada

[2] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada

[3] London Reg Canc Ctr, London, ON, Canada

[4] Canadian Myeloma Res Grp, Vaughan, ON, Canada

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Ottawa Hosp, Ottawa, ON, Canada

[7] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[8] Univ Saskatchewan, Saskatoon Canc Ctr, Saskatoon, SK, Canada

[9] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[10] McGill Univ, Montreal, PQ, Canada

[11] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada

[12] Allan Blair Canc Ctr, Regina, SK, Canada

[13] Vancouver Gen Hosp, BC Canc Agcy, Vancouver, BC, Canada

[14] St Johns Hosp, St John, NB, Canada

[15] Canc Care Manitoba, Winnipeg, MB, Canada

来源：

CANCER MEDICINE | 2023年 / 12卷 / 04期

关键词：

dosing; lenalidomide; multiple myeloma; transplant-ineligible; SURVIVAL; STRATEGY;

D O I：

10.1002/cam4.5245

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant-ineligible patients with multiple myeloma (MM) that received lenalidomide-dexamethasone as front-line treatment was conducted to understand the impact of lenalidomide dosing. Starting dose modifications were common, 42% of patients started on lenalidomide <25 mg with normal renal function. During treatment course, 35% of patients required further dose reduction. Dose reductions in the first year did not have an impact on progression free survival or overall survival. Further studies need to be conducted to understand the impact of dosing strategies of anti-MM agents in the real world.

引用

页码：4357 / 4362

页数：6

共 50 条

[21] ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE REAL WORLD
Yamazaki, E.
Takahashi, H.
Ishibashi, D.
Kishimoto, K.
Miyashita, K.
Numata, A.
Hattori, Y.
Kawasaki, R.
Koharazawa, H.
Fujimaki, K.
Taguchi, J.
Fujita, H.
Sakai, R.
Fujisawa, S.
Harano, H.
Nakajima, H.
[J]. HAEMATOLOGICA, 2017, 102 : 785 - 785
[22] Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
Martinez-Lopez, Joaquin
Mendes, Joao
Luke, Emily
Kluth, Caspian
Salmon, Phoebe
Bailey, Abigail
Ribbands, Amanda
Gay, Francesca
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S198 - S199
[23] Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs
Hari, Parameswaran
Ung, Brian
Abouzaid, Safiya
Ni, Quanhong
Parikh, Kejal
Agarwal, Amit
[J]. BLOOD, 2017, 130
[24] Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database
Dhakal, Binod
Einsele, Hermann
Schecter, Jordan
Deraedt, William
Lendvai, Nikoletta
Slaughter, Ana
Lonardi, Carolina
Nair, Sandhya
He, Jianming
Voelker, Jennifer
Cost, Patricia
Valluri, Satish
Pacaud, Lida
Yalniz, Fevzi
Yong, Kwee
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S168 - S168
[25] The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials
Fiala, Mark
Dukeman, James
Stockerl-Goldstein, Keith
Tomasson, Michael
Wildes, Tanya
Vij, Ravi
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E55 - E56
[26] The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials
Fiala, Mark A.
Dukeman, James
Stockerl-Goldstein, Keith
Tomasson, Michael H.
Wildes, Tanya M.
Vij, Ravi
[J]. BLOOD, 2016, 128 (22)
[27] Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a "real-world" study: experiences of the Polish Myeloma Group
Charlinski, Grzegorz
Tyczynska, Agata
Malecki, Bartosz
Fornagiel, Szymon
Barchnicka, Agnieszka
Kolkowska, Agnieszka
Kopinska, Anna
Usnarska-Zubkiewicz, Lidia
Robak, Pawel
Waszczuk-Gajda, Anna
Krzystanski, Mateusz
Jurczyszyn, Artur
[J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (06): : 527 - 534
[28] Real-World Treatment Patterns and Outcomes of Patients with Newly Diagnosed Multiple Myeloma: An Analysis Using National Health Insurance Service Database
Lee, YooSun
Yoon, Junghyun
Park, Boyoung
Eom, Hyeon-Seok
[J]. BLOOD, 2022, 140 : 5156 - 5157
[29] Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada
Jimenez-Zepeda, Victor H.
Chen, Guanmin
Shaw, Eileen
Farris, Megan S.
Cowling, Tara
Tay, Jason
[J]. LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2557 - 2564
[30] Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice
Zhong, Liye
Wei, Yongqiang
Ping, Baohong
Li, Xin
Peng, Hongling
Li, Yongqain
Tian, Yuyang
Liu, Zelin
Luo, Jun
Su, Yongzhong
Chen, Haifei
He, Yanjuan
Li, Hongliang
Wu, Congming
Sun, Zhiqiang
Shi, Keqian
Li, Xiaoliang
Zhang, Qing
Hu, Guoyu
Huang, Gang
Huang, Zhenqian
Wang, Weida
Xia, Zhongjun
[J]. BLOOD, 2021, 138

← 1 2 3 4 5 →